<p>The anticholinergic actvity of imipramine can produce dry mucous membranes, blurred vision, increased intraocular pressure, hyperthermia, constipation, adynamic ileus, urinary retention, delayed micturition, and dilation of the urinary tract <sup class="text-reference-group"><a class="reference-popover-link" data-content="TOXNET: Imipramine" href="#reference-L1360">16</a></sup>.</p><p>Central nervous system and neuromuscular effects include drowsiness, lethargy, fatigue, agitation, excitement, nightmares, restlessness, insomnia, confusion, disturbed concentration, disorientation, delusions, and hallucinations.</p><p>Effects on the GI tract include anorexia, nausea and vomiting, diarrhea, abdominal cramps, increases in pancreatic enzymes, epigastric distress, stomatitis, peculiar taste, and black tongue.</p><p>Rarely agranulocytosis, thrombocytopenia, eosinophilia, leukopenia, and purpura have occured.</p><p>Infants whose mothers were receiving tricyclic antidepressants prior to delivery have experienced cardiac problems, irritability, respiratory distress, muscle spasms, seizures, and urinary retention.</p><p>Serotonin syndrome can occur when used in conjunction with other pro-serotonergic drugs.</p><p>Rat
- Oral 250 mg/kg
- Intraperitoneal 79mg/kg
- Subcutaneous 250 mg/kg
- Intravenous 15.9 mg/kg</p><p>Mouse
- Oral 188 mg/kg
- Intraperitoneal 51.6 mg/kg
- Subcutaneous 195 μg/kg
- Intravenous 21 mg/kg</p><p>Human range of toxicity is considered to include single dosages greater than 5 mg/kg.</p>